ExodusPoint Capital Management’s Tvardi Therapeutics TVRD Stock Holding History

ExodusPoint Capital Management’s Portfolio TVRD Stock Details TVRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-5,935	Closed	-$1.05M	–	2320
2023 Q1	$1.05M	Sell	5,935 -4,378	-42%	-$1.47M	0.01%	1127
2022 Q4	$3.99M	Buy	10,313 +6,687	+184%	+$2.54M	0.06%	412
2022 Q3	$1.22M	Buy	3,626 +105	+3%	+$38K	0.02%	1026
2022 Q2	$1.16M	Buy	3,521 +2,100	+148%	+$737K	0.01%	1013
2022 Q1	$622K	Buy	1,421 +638	+81%	+$262K	0.01%	1407
2021 Q4	$343K	Buy	+783	New	+$393K	﹤0.01%	1608
2021 Q3	–	Sell	-497	Closed	-$255K	–	2750
2021 Q2	$255K	Sell	497 -946	-66%	-$599K	﹤0.01%	1836
2021 Q1	$1.13M	Buy	+1,443	New	+$988K	0.02%	847
2020 Q4	–	Sell	-608	Closed	-$278K	–	2464
2020 Q3	$278K	Buy	608 +150	+33%	+$87.1K	0.01%	1320
2020 Q2	$282K	Buy	+458	New	+$253K	0.01%	1347
2020 Q1	–	Sell	-577	Closed	-$334K	–	1733
2019 Q4	$334K	Buy	+577	New	+$405K	0.01%	1093

Other funds holding TVRD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ExodusPoint Capital Management's TVRD Position: Q2 2023 in Review

ExodusPoint Capital Management sold out of Tvardi Therapeutics (TVRD) in Q2 2023, closing a stake of 5,935 shares — an estimated $1.05M sold.

ExodusPoint Capital Management first reported a position in TVRD in Q4 2019 and held it in 11 quarters. The position peaked at $3.99M in Q4 2022. 137 funds tracked by Wall St. Rank hold TVRD as of Q2 2023.

ExodusPoint Capital Management reported no remaining Tvardi Therapeutics position as of Q2 2023 after selling out during the quarter.
ExodusPoint Capital Management sold 5,935 Tvardi Therapeutics shares in Q2 2023, an estimated $1.05M.
ExodusPoint Capital Management first reported a position in Tvardi Therapeutics in Q4 2019 and held it in 11 quarters.
ExodusPoint Capital Management's Tvardi Therapeutics position peaked at $3.99M in Q4 2022.
137 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2023.

Based on ExodusPoint Capital Management's 13F filing for Q2 2023, filed 11 Aug 2023.